

CORRECTION

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Chem. Sci.*, 2020, **11**, 12588**Correction: A straightforward approach to antibodies recognising cancer specific glycopeptidic neopeptides**Hajime Wakui,^a Yoshikazu Tanaka,^b Toyoyuki Ose,^c Isamu Matsumoto,^c Koji Kato,^d Yao Min,^c Taro Tachibana,^e Masaharu Sato,^f Kentaro Naruchi,^f Fayna Garcia Martin,^a Hiroshi Hinou^a and Shin-Ichiro Nishimura^{*a}

DOI: 10.1039/d0sc90254c

rsc.li/chemical-scienceCorrection for 'A straightforward approach to antibodies recognising cancer specific glycopeptidic neopeptides' by Hajime Wakui *et al.*, *Chem. Sci.*, 2020, **11**, 4999–5006, DOI: 10.1039/D0SC00317D.

The authors regret that part Fig. 1b was missing from the version of Fig. 1 shown in the original article. The correct version of Fig. 1 is presented below.

^aField of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, Sapporo, 001-0021, Japan. E-mail: shin@sci.hokudai.ac.jp^bGraduate School of Life Sciences, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai 980-8577, Japan^cField of X-ray Structural Biology, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University, N10 W8, Kita-ku, Sapporo 060-0810, Japan^dResearch Institute for Interdisciplinary Science and Graduate School of Natural Science and Technology, Okayama University, 3-1-1, Tsushima-naka, Kita-ku, Okayama 700-8530, Japan^eDepartment of Bioengineering, Graduate School of Engineering, Osaka City University, Sumiyoshi-ku, Osaka 558-8585, Japan^fMedicinal Chemistry Pharmaceuticals, Co., Ltd., N9 W15, Chuo-ku, Sapporo 060-0009, Japan




Fig. 1 Generation of epitope-defined anti-MUC1 antibodies. (a) A strategy for the generation of antibodies targeting glycopeptidic epitopes by using synthetic glycopeptides designed for the streamlined process from the immunization of "conformational glycopeptidic neoepitopes", antibody selection, and characterization. (b) A list of compounds used in this study. Compound **1** was conjugated with KLH by using the Cys residue (red) or aminoxy-functionalized nanoparticles^{25–27} by using the ketone linker (blue) and used for the immunization. The first screening was performed by ELISA immobilizing compounds **1** and **2** using Cys residue (red) to collect antibodies binding selectively with glycopeptide **1**. Compound **3** was used for the co-crystallization with SN-101. Compounds **4–24** were displayed on the microarray by means of the ketone linker (blue) and employed for epitope mapping analysis. Compound **25** was used for the SPR analysis by immobilizing with Cys residue (red).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

